ClinConnect ClinConnect Logo
Search / Trial NCT05436964

Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Major Abdominal Surgery

Launched by CHINESE PLA GENERAL HOSPITAL · Jun 26, 2022

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Dexmedetomidine

ClinConnect Summary

This clinical trial is studying the effects of a medication called dexmedetomidine, which is given during surgery, on preventing a condition known as postoperative delirium in older patients who are having major abdominal surgery. Postoperative delirium is a type of confusion that can happen after surgery, especially in elderly patients. The researchers want to see if using dexmedetomidine can help reduce the chances of this confusion, as well as how much pain relief medication patients need after the surgery and their pain levels.

To participate in this trial, patients need to be over 65 years old and scheduled for elective (planned) major abdominal surgery. It's important that they can provide written consent to join the study. However, some patients may not be eligible, such as those with significant cognitive impairments, certain heart or kidney conditions, or very high or low body weight. Participants can expect to receive the standard care for their surgery along with the dexmedetomidine treatment, and they will be monitored for any changes in their mental state and pain management needs during their recovery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients over 65 years old
  • Patients undergoing elective major abdominal surgery
  • Written informed consent was obtained
  • Exclusion Criteria:
  • Patients with severe preoperative cognitive impairment (MMSE ≤ 20) who are unable to undergo a follow-up evaluation.
  • Patients with history of psychiatric or neurological disorders.
  • Patients with body mass index ≤ 18 or ≥ 30
  • Patients with severe bradycardia (heart rate less than 40 beats per minute)
  • Patients with pathological sinus node syndrome or grade 2 or greater AV block
  • Patients with severe hepatic or renal insufficiency.
  • Patients with severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg)

About Chinese Pla General Hospital

The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.

Locations

Beijing, , China

Beijing, , China

Beijing, Beijing, China

Wuhan, , China

Patients applied

0 patients applied

Trial Officials

Hao Li

Principal Investigator

Chinese PLA General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials